235.8K XNAS Volume
XNAS 19 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Vickie L. Capps | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 3,093 | 3,093 (0%) | 0% | 0 | Common Stock | |
| Vickie L. Capps | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 35,270 | 35,270 | - | - | Employee Stock Option (Right to Buy) | |
| Massimo Calafiore | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 17.43 per share. | 05 Mar 2025 | 9,914 | 222,404 (1%) | 0% | 17.4 | 172,801 | Common Stock |
| Lucas Vitale | CP&BO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 14,723 | 139,604 (0%) | 0% | 0 | Common Stock | |
| Jorge Andres Cedron | CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 41,908 | 41,908 | - | - | Employee Stock Option (Right to Buy) | |
| Jorge Andres Cedron | CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 17,668 | 46,316 (0%) | 0% | 0 | Common Stock | |
| Geoffrey C. Gillespie | CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 3,681 | 42,817 (0%) | 0% | 0 | Common Stock | |
| Geoffrey C. Gillespie | CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 8,731 | 8,731 | - | - | Employee Stock Option (Right to Buy) | |
| Massimo Calafiore | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 88,339 | 212,490 (1%) | 0% | 0 | Common Stock | |
| Massimo Calafiore | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 209,541 | 209,541 | - | - | Employee Stock Option (Right to Buy) | |
| Lucas Vitale | CP&BO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 34,924 | 34,924 | - | - | Employee Stock Option (Right to Buy) | |
| Julie B. Andrews | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 34,600 | 62,912 (0%) | 0% | 0 | Common Stock | |
| Julie B. Andrews | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 82,070 | 82,070 | - | - | Employee Stock Option (Right to Buy) | |
| Geoffrey C. Gillespie | CAO | Sale of securities on an exchange or to another person at price $ 18.08 per share. | 03 Feb 2025 | 187 | 39,136 (0%) | 0% | 18.1 | 3,381 | Common Stock |
| Geoffrey C. Gillespie | CAO | Sale of securities on an exchange or to another person at price $ 17.79 per share. | 03 Feb 2025 | 767 | 39,323 (0%) | 0% | 17.8 | 13,645 | Common Stock |
| Julie B. Andrews | CFO | Sale of securities on an exchange or to another person at price $ 17.89 per share. | 16 Jan 2025 | 4,655 | 28,312 (0%) | 0% | 17.9 | 83,278 | Common Stock |
| Geoffrey C. Gillespie | CAO | Sale of securities on an exchange or to another person at price $ 17.14 per share. | 10 Jan 2025 | 227 | 40,090 (0%) | 0% | 17.1 | 3,891 | Common Stock |
| Geoffrey C. Gillespie | CAO | Sale of securities on an exchange or to another person at price $ 16.83 per share. | 10 Jan 2025 | 248 | 40,317 (0%) | 0% | 16.8 | 4,174 | Common Stock |
| Massimo Calafiore | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 17.14 per share. | 10 Jan 2025 | 9,203 | 124,151 (0%) | 0% | 17.1 | 157,757 | Common Stock |
| Massimo Calafiore | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 16.83 per share. | 10 Jan 2025 | 10,078 | 133,354 (0%) | 0% | 16.8 | 169,619 | Common Stock |
| C. Geoffrey Gillespie | CAO | Sale of securities on an exchange or to another person at price $ 17.85 per share. | 17 Dec 2024 | 26 | 41,041 (0%) | 0% | 17.8 | 464 | Common Stock |
| Wayne C. Burris | Director | Grant, award, or other acquisition of securities at price $ 12.87 per share. | 18 Jun 2024 | 15,152 | 31,698 (0%) | 0% | 12.9 | 195,006 | Common Stock |
| Jason M. Hannon | Director | Grant, award, or other acquisition of securities at price $ 12.87 per share. | 18 Jun 2024 | 15,152 | 49,364 (0%) | 0% | 12.9 | 195,006 | Common Stock |
| Michael M. Finegan | Director | Grant, award, or other acquisition of securities at price $ 12.87 per share. | 18 Jun 2024 | 21,368 | 29,718 (0%) | 0% | 12.9 | 275,006 | Common Stock |
| John B. Henneman | Director | Grant, award, or other acquisition of securities at price $ 12.87 per share. | 18 Jun 2024 | 15,152 | 63,914 (0%) | 0% | 12.9 | 195,006 | Common Stock |
| Alan L. Bazaar | Director | Grant, award, or other acquisition of securities at price $ 12.87 per share. | 18 Jun 2024 | 15,152 | 24,088 (0%) | 0% | 12.9 | 195,006 | Common Stock |
| Charles R. Kummeth | Director | Grant, award, or other acquisition of securities at price $ 12.87 per share. | 18 Jun 2024 | 15,152 | 38,502 (0%) | 0% | 12.9 | 195,006 | Common Stock |
| Michael E. Paolucci | Director | Grant, award, or other acquisition of securities at price $ 12.87 per share. | 18 Jun 2024 | 15,152 | 66,766 (0%) | 0% | 12.9 | 195,006 | Common Stock |
| Kimberley A. Elting | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.42 per share. | 08 Jun 2024 | 4,267 | 227,747 (1%) | 0% | 13.4 | 57,263 | Common Stock |
| Jorge Andres Cedron | CLO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 64,817 | 64,817 | - | - | Employee Stock Option (Right to Buy) | |
| Jorge Andres Cedron | CLO | Grant, award, or other acquisition of securities at price $ 13.09 per share. | 15 Apr 2024 | 28,648 | 28,648 (0%) | 0% | 13.1 | 375,002 | Common Stock |
| Kimberley A. Elting | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.95 per share. | 11 Apr 2024 | 2,938 | 232,014 (1%) | 0% | 13.9 | 40,985 | Common Stock |
| Catherine M. Burzik | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.23 per share. | 08 Apr 2024 | 47,486 | 112,803 (0%) | 0% | 14.2 | 675,726 | Common Stock |
| Kimberley A. Elting | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.06 per share. | 01 Apr 2024 | 2,031 | 234,952 (1%) | 0% | 14.1 | 28,556 | Common Stock |
| Geoffrey C. Gillespie | CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.06 per share. | 01 Apr 2024 | 70 | 40,772 (0%) | 0% | 14.1 | 984 | Common Stock |
| Geoffrey C. Gillespie | CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 8,381 | 8,381 | - | - | Employee Stock Option (Right to Buy) | |
| Geoffrey C. Gillespie | CAO | Grant, award, or other acquisition of securities at price $ 13.74 per share. | 15 Mar 2024 | 3,639 | 40,842 (0%) | 0% | 13.7 | 50,000 | Common Stock |
| A. Elting Kimberley | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.27 per share. | 01 Feb 2024 | 2,015 | 236,983 (1%) | 0% | 14.3 | 28,754 | Common Stock |
| Michael M. Finegan | Director | Grant, award, or other acquisition of securities at price $ 13.89 per share. | 31 Jan 2024 | 8,350 | 8,350 (0%) | 0% | 13.9 | 115,982 | Common Stock |
| Alan L. Bazaar | Director | Grant, award, or other acquisition of securities at price $ 13.89 per share. | 31 Jan 2024 | 8,936 | 8,936 (0%) | 0% | 13.9 | 124,121 | Common Stock |
| Charles R. Kummeth | Director | Grant, award, or other acquisition of securities at price $ 13.89 per share. | 31 Jan 2024 | 8,350 | 23,350 (0%) | 0% | 13.9 | 115,982 | Common Stock |
| Julie B. Andrews | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 76,878 | 76,878 | - | - | Employee Stock Option (right to buy) | |
| B. Julie Andrews | CFO | Grant, award, or other acquisition of securities at price $ 13.65 per share. | 15 Jan 2024 | 32,967 | 32,967 (0%) | 0% | 13.7 | 450,000 | Common Stock |
| J. Kenny Kevin | President of Global Spine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2024 | 5,959 | 147,321 (0%) | 0% | 0 | Common Stock | |
| Calafiore Massimo | President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2024 | 392,005 | 392,005 | - | - | Employee Stock Option (right to buy) | |
| Massimo Calafiore | President & CEO | Grant, award, or other acquisition of securities at price $ 13.29 per share. | 08 Jan 2024 | 141,084 | 141,084 (0%) | 0% | 13.3 | 1,875,006 | Common Stock |
| Kenny Kevin J. | President of Global Spine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2024 | 5,959 | 0 | - | - | Performance Share Units | |
| Kenny Kevin J. | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.29 per share. | 08 Jan 2024 | 1,511 | 145,810 (0%) | 0% | 13.3 | 20,081 | Common Stock |
| C. Gillespie Geoffrey | VP, Controller, Interim CFO | Grant, award, or other acquisition of securities at price $ 13.29 per share. | 05 Jan 2024 | 4,703 | 37,385 (0%) | 0% | 13.3 | 62,503 | Common Stock |
| Geoffrey Gillespie C. | VP, Controller, Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.67 per share. | 05 Jan 2024 | 459 | 32,682 (0%) | 0% | 12.7 | 5,816 | Common Stock |
| A. Kimberley Elting | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.67 per share. | 05 Jan 2024 | 5,228 | 220,187 (1%) | 0% | 12.7 | 66,239 | Common Stock |
| A. Kimberley Elting | President, Global Orthopedics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 43,867 | 43,867 | - | - | Employee Stock Option (Right to Buy) | |
| Kimberley Elting A. | President, Global Orthopedics | Grant, award, or other acquisition of securities at price $ 13.29 per share. | 05 Jan 2024 | 18,811 | 238,998 (1%) | 0% | 13.3 | 249,998 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.67 per share. | 05 Jan 2024 | 2,955 | 141,362 (0%) | 0% | 12.7 | 37,440 | Common Stock |
| Gillespie C. Geoffrey | VP, Controller, Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 10,967 | 10,967 | - | - | Employee Stock Option (Right to Buy) | |
| A. Kimberley Elting | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.96 per share. | 03 Jan 2024 | 1,778 | 225,415 (1%) | 0% | 13.0 | 23,043 | Common Stock |
| Bazaar L. Alan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 47,652 | 47,652 | - | - | Stock Option (right to buy) | |
| Michael Finegan M. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 47,652 | 47,652 | - | - | Stock Option (right to buy) | |
| Kummeth Charles R. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 47,652 | 47,652 | - | - | Stock Option (right to buy) | |
| Alan Bazaar L. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Dec 2023 | 8,936 | 0 (0%) | 0% | 0 | Common Stock | |
| Burris Wayne C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 47,652 | 47,652 | - | - | Stock Option (right to buy) | |
| Geoffrey C. Gillespie | VP, Controller, Interim CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.12 per share. | 15 Dec 2023 | 24 | 33,141 (0%) | 0% | 12.1 | 291 | Common Stock |
| L. Bazaar Alan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2023 | 8,936 | 8,936 (0%) | 0% | 0 | Common Stock | |
| J. Kevin Kenny | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.79 per share. | 04 Dec 2023 | 609 | 144,317 (0%) | 0% | 10.8 | 6,571 | Common Stock |
| Catherine M. Burzik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2023 | 3,589 | 37,949 (0%) | 0% | 0 | Common Stock | |
| Wayne C. Burris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2023 | 10,163 | 16,546 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Kenny | President of Global Spine | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 24 May 2023 | 4,367 | 146,307 (0%) | 0% | 19 | 82,973 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 24 May 2023 | 3,876 | 142,431 (0%) | 0% | 19 | 73,644 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.77 per share. | 11 Apr 2023 | 1,469 | 148,087 (0%) | 0% | 17.8 | 26,104 | Common Stock |
| Kimberley A. Elting | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.77 per share. | 11 Apr 2023 | 2,938 | 177,841 (0%) | 0% | 17.8 | 52,208 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 17,061 | 17,061 | - | - | Employee Stock Option (Right to Buy) | |
| Kevin J. Kenny | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.75 per share. | 03 Apr 2023 | 1,956 | 141,275 (0%) | 0% | 16.8 | 32,763 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 7,449 | 148,724 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 5,959 | 5,959 | - | - | Performance Share Units | |
| Kimberley A. Elting | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.75 per share. | 03 Apr 2023 | 2,385 | 180,779 (0%) | 0% | 16.8 | 39,949 | Common Stock |
| Jon Carl Serbousek | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.75 per share. | 03 Apr 2023 | 6,141 | 346,827 (1%) | 0% | 16.8 | 102,862 | Common Stock |
| Keith C. Valentine | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.60 per share. | 28 Feb 2023 | 16,290 | 377,741 (1%) | 0% | 20.6 | 335,574 | Common Stock |
| Patrick L. Keran | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.60 per share. | 28 Feb 2023 | 3,792 | 84,407 (0%) | 0% | 20.6 | 78,115 | Common Stock |
| John J. Bostjancic | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.60 per share. | 28 Feb 2023 | 3,783 | 99,670 (0%) | 0% | 30.6 | 115,760 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.54 per share. | 01 Feb 2023 | 2,287 | 143,231 (0%) | 0% | 21.5 | 49,262 | Common Stock |
| Kimberley A. Elting | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.54 per share. | 01 Feb 2023 | 2,015 | 183,164 (0%) | 0% | 21.5 | 43,403 | Common Stock |
| Jon Carl Serbousek | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.54 per share. | 01 Feb 2023 | 5,142 | 352,968 (1%) | 0% | 21.5 | 110,759 | Common Stock |
| Keith C. Valentine | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.22 per share. | 30 Jan 2023 | 5,824 | 394,031 (2%) | 0% | 21.2 | 123,585 | Common Stock |
| Patrick L. Keran | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.22 per share. | 30 Jan 2023 | 999 | 88,199 (0%) | 0% | 21.2 | 21,199 | Common Stock |
| John J. Bostjancic | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.22 per share. | 30 Jan 2023 | 1,694 | 103,453 (0%) | 0% | 21.2 | 35,947 | Common Stock |
| Catherine M. Burzik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 14,354 | 33,056 (0%) | 0% | 0 | Common Stock | |
| Jason M. Hannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 14,354 | 31,587 (0%) | 0% | 0 | Common Stock | |
| Keith C. Valentine | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 338,264 | 338,264 | - | - | Employee Stock Option (Right to Buy) | |
| Keith C. Valentine | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 140,515 | 399,855 (2%) | 0% | 0 | Common Stock | |
| John B. Henneman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 14,354 | 48,762 (0%) | 0% | 0 | Common Stock | |
| Stuart M. Essig | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 14,354 | 205,966 (1%) | 0% | 0 | Common Stock | |
| Patrick L. Keran | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 35,128 | 89,198 (0%) | 0% | 0 | Common Stock | |
| Patrick L. Keran | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 84,566 | 84,566 | - | - | Employee Stock Option (Right to Buy) | |
| James Hinrichs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 14,354 | 77,859 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Kenny | President of Global Spine | Other type of transaction at price $ 0.00 per share. | 05 Jan 2023 | 832 | 146,350 (0%) | 0% | 0 | Common Stock | |
| Michael E. Paolucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 14,354 | 48,989 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | President, Global Orthopedics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 12,229 | 164,687 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | President, Global Orthopedics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 84,566 | 84,566 | - | - | Employee Stock Option (Right to Buy) | |
| Kimberley A. Elting | President, Global Orthopedics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 20,492 | 185,179 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | President, Global Orthopedics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 11,534 | 152,458 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | President, Global Orthopedics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 35,129 | 140,924 (0%) | 0% | 0 | Common Stock | |
| John J. Bostjancic | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 84,566 | 84,566 | - | - | Employee Stock Option (Right to Buy) | |
| John J. Bostjancic | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 35,128 | 105,147 (0%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 81,967 | 358,110 (1%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 45,872 | 235,379 (1%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 81,967 | 358,110 (1%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 40,764 | 276,143 (1%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 40,764 | 276,143 (1%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 45,872 | 235,379 (1%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | President, Global Orthopedics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 11,710 | 105,795 (0%) | 0% | 0 | Common Stock | |
| Thomas A. West | Director | Grant, award, or other acquisition of securities at price $ 13.65 per share. | 31 Dec 2022 | 512 | 7,055 (0%) | 0% | 13.7 | 6,989 | Common Stock |
| Lilly Marks | Director | Grant, award, or other acquisition of securities at price $ 13.65 per share. | 31 Dec 2022 | 293 | 37,813 (0%) | 0% | 13.6 | 3,999 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.02 per share. | 05 Dec 2022 | 984 | 72,407 (0%) | 0% | 20.0 | 19,700 | Common Stock |
| Jon Carl Serbousek | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.21 per share. | 01 Nov 2022 | 2,369 | 186,551 (0%) | 0% | 16.2 | 38,401 | Common Stock |
| Kimberley A. Elting | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.53 per share. | 05 Sep 2022 | 365 | 94,085 (0%) | 0% | 19.5 | 7,128 | Common Stock |
| Jon Carl Serbousek | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.77 per share. | 05 Aug 2022 | 1,450 | 188,920 (0%) | 0% | 22.8 | 33,017 | Common Stock |
| Catherine M. Burzik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 8,844 | 17,443 (0%) | 0% | 0 | Common Stock | |
| Jason M. Hannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,383 | 16,501 (0%) | 0% | 0 | Common Stock | |
| James Hinrichs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,383 | 62,727 (0%) | 0% | 0 | Common Stock | |
| Michael E. Paolucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,383 | 33,903 (0%) | 0% | 0 | Common Stock | |
| John Sicard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,383 | 21,615 (0%) | 0% | 0 | Common Stock | |
| Thomas A. West | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,383 | 6,543 (0%) | 0% | 0 | Common Stock | |
| Lilly Marks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,383 | 37,520 (0%) | 0% | 0 | Common Stock | |
| Wayne C. Burris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,383 | 6,383 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2022 | 14,937 | 69,625 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | President, Global Orthopedics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2022 | 29,874 | 94,450 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2022 | 14,937 | 107,679 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Kenny | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 1,202 | 55,441 (0%) | 0% | 33.0 | 39,714 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 753 | 54,688 (0%) | 0% | 33.0 | 24,879 | Common Stock |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 334 | 64,576 (0%) | 0% | 33.0 | 11,035 | Common Stock |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 354 | 66,941 (0%) | 0% | 33.0 | 11,696 | Common Stock |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 829 | 66,112 (0%) | 0% | 33.0 | 27,390 | Common Stock |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 1,202 | 64,910 (0%) | 0% | 33.0 | 39,714 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 1,317 | 93,490 (0%) | 0% | 33.0 | 43,514 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 363 | 92,742 (0%) | 0% | 33.0 | 11,994 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 385 | 93,105 (0%) | 0% | 33.0 | 12,720 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 867 | 94,807 (0%) | 0% | 33.0 | 28,646 | Common Stock |
| Jon Carl Serbousek | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 2,041 | 188,839 (0%) | 0% | 33.0 | 67,435 | Common Stock |
| Jon Carl Serbousek | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 3,899 | 190,880 (0%) | 0% | 33.0 | 128,823 | Common Stock |
| Paul Gonsalves | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.04 per share. | 01 Apr 2022 | 687 | 25,716 (0%) | 0% | 33.0 | 22,698 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 20,492 | 56,643 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 20,492 | 20,492 | - | - | Performance Share Units | |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 20,492 | 20,492 | - | - | Performance Share Units | |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 20,492 | 67,295 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 22,131 | 22,131 | - | - | Performance Share Units | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 22,131 | 95,674 (0%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 81,967 | 194,779 (1%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 81,967 | 81,967 | - | - | Performance Share Units | |
| Paul Gonsalves | President, Global Orthopedics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 9,836 | 9,836 | - | - | Performance Share Units | |
| Paul Gonsalves | President, Global Orthopedics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 9,836 | 26,403 (0%) | 0% | 0 | Common Stock | |
| Thomas A. West | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2021 | 29,450 | 29,450 | - | - | Stock Option (right to buy) | |
| Michael E. Paolucci | Director | Purchase of securities on an exchange or from another person at price $ 31.15 per share. | 22 Nov 2021 | 2,000 | 27,141 (0%) | 0% | 31.2 | 62,300 | Common Stock |
| Catherine M. Burzik | Director | Purchase of securities on an exchange or from another person at price $ 30.27 per share. | 19 Nov 2021 | 1,660 | 7,947 (0%) | 0% | 30.3 | 50,248 | Common Stock |
| Douglas C. Rice | CFO | Purchase of securities on an exchange or from another person at price $ 30.05 per share. | 19 Nov 2021 | 1,400 | 73,543 (0%) | 0% | 30.1 | 42,070 | Common Stock |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Purchase of securities on an exchange or from another person at price $ 30.34 per share. | 18 Nov 2021 | 1,000 | 46,803 (0%) | 0% | 30.3 | 30,340 | Common Stock |
| Jon Carl Serbousek | Director, CEO | Purchase of securities on an exchange or from another person at price $ 31.14 per share. | 18 Nov 2021 | 1,670 | 112,812 (0%) | 0% | 31.1 | 52,004 | Common Stock |
| Jon Carl Serbousek | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.87 per share. | 01 Nov 2021 | 2,369 | 109,903 (0%) | 0% | 36.9 | 87,345 | Common Stock |
| Wayne C. Burris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 22,184 | 22,184 | - | - | Stock Option (right to buy) | |
| Paul Gonsalves | President, Global Orthopedics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.59 per share. | 11 Sep 2021 | 1,045 | 16,567 (0%) | 0% | 40.6 | 42,417 | Common Stock |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.69 per share. | 05 Sep 2021 | 365 | 44,953 (0%) | 0% | 42.7 | 15,582 | Common Stock |
| Jon Carl Serbousek | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.98 per share. | 05 Aug 2021 | 1,450 | 112,272 (0%) | 0% | 38.0 | 55,071 | Common Stock |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.48 per share. | 03 Jul 2021 | 346 | 45,318 (0%) | 0% | 40.5 | 14,006 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.48 per share. | 03 Jul 2021 | 373 | 70,370 (0%) | 0% | 40.5 | 15,099 | Common Stock |
| Alexis V. Lukianov | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 4,313 | 21,027 (0%) | 0% | 0 | Common Stock | |
| Catherine M. Burzik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 21,361 | 21,361 | - | - | Stock Option (right to buy) | |
| Catherine M. Burzik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 5,976 | 5,976 (0%) | 0% | 0 | Common Stock | |
| Jason M. Hannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 4,313 | 9,431 (0%) | 0% | 0 | Common Stok | |
| James Hinrichs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 4,313 | 55,594 (0%) | 0% | 0 | Common Stock | |
| Michael E. Paolucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 4,313 | 24,814 (0%) | 0% | 0 | Common Stock | |
| John Sicard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 4,313 | 15,232 (0%) | 0% | 0 | Common Stock | |
| Lilly Marks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 4,313 | 30,573 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 12,229 | 12,229 | - | - | Performance Share Units | |
| Kevin J. Kenny | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.93 per share. | 01 Apr 2021 | 753 | 30,268 (0%) | 0% | 42.9 | 32,326 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 12,229 | 31,021 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 12,229 | 48,720 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 12,229 | 12,229 | - | - | Performance Share Units | |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.93 per share. | 01 Apr 2021 | 335 | 44,217 (0%) | 0% | 42.9 | 14,382 | Common Stock |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.93 per share. | 01 Apr 2021 | 829 | 44,552 (0%) | 0% | 42.9 | 35,589 | Common Stock |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.93 per share. | 01 Apr 2021 | 2,985 | 45,381 (0%) | 0% | 42.9 | 128,146 | Common Stock |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.93 per share. | 01 Apr 2021 | 354 | 48,366 (0%) | 0% | 42.9 | 15,197 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.93 per share. | 01 Apr 2021 | 363 | 66,478 (0%) | 0% | 42.9 | 15,584 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.93 per share. | 01 Apr 2021 | 867 | 66,841 (0%) | 0% | 42.9 | 37,220 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.93 per share. | 01 Apr 2021 | 3,029 | 67,708 (0%) | 0% | 42.9 | 130,035 | Common Stock |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 13,394 | 13,394 | - | - | Performance Share Units | |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.93 per share. | 01 Apr 2021 | 385 | 70,737 (0%) | 0% | 42.9 | 16,528 | Common Stock |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 13,394 | 71,122 (0%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.93 per share. | 01 Apr 2021 | 2,784 | 113,722 (0%) | 0% | 42.9 | 119,517 | Common Stock |
| Jon Carl Serbousek | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 40,764 | 116,506 (0%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 40,764 | 40,764 | - | - | Performance Share Units | |
| Paul Gonsalves | President, Global Extremities | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 6,988 | 17,612 (0%) | 0% | 0 | Common Stock | |
| Paul Gonsalves | President, Global Extremities | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 6,988 | 6,988 | - | - | Performance Share Units | |
| Jon Carl Serbousek | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.26 per share. | 01 Nov 2020 | 1,466 | 74,181 (0%) | 0% | 31.3 | 45,827 | Common Stock |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.40 per share. | 26 Sep 2020 | 550 | 35,965 (0%) | 0% | 29.4 | 16,170 | Common Stock |
| Paul Gonsalves | President, Global Extremities | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2020 | 32,945 | 32,945 | - | - | Stock Option (right to buy) | |
| Paul Gonsalves | President, Global Extremities | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2020 | 10,624 | 10,624 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | Chief Legal & Develop. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.79 per share. | 05 Sep 2020 | 365 | 36,515 (0%) | 0% | 28.8 | 10,508 | Common Stock |
| Jon Carl Serbousek | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.24 per share. | 07 Aug 2020 | 897 | 75,647 (0%) | 0% | 33.2 | 29,816 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.34 per share. | 08 Jul 2020 | 1,456 | 55,706 (0%) | 0% | 30.3 | 44,175 | Common Stock |
| Kimberley A. Elting | Chief Legal & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.19 per share. | 03 Jul 2020 | 346 | 36,880 (0%) | 0% | 32.2 | 11,138 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.19 per share. | 01 Jul 2020 | 363 | 47,175 (0%) | 0% | 32.2 | 11,685 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.34 per share. | 01 Jul 2020 | 395 | 47,538 (0%) | 0% | 32.3 | 12,774 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.19 per share. | 01 Jul 2020 | 373 | 57,162 (0%) | 0% | 32.2 | 12,007 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.34 per share. | 01 Jul 2020 | 377 | 57,535 (0%) | 0% | 32.3 | 12,192 | Common Stock |
| Alexis V. Lukianov | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 4,588 | 16,083 (0%) | 0% | 0 | Common Stock | |
| Jason M. Hannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 24,701 | 24 | - | - | Stock Option (right to buy) | |
| Jason M. Hannon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 4,588 | 4,588 (0%) | 0% | 0 | Common Stock | |
| Maria Sainz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 4,588 | 40,871 (0%) | 0% | 0 | Common Stock | |
| Ronald A. Matricaria | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 8,520 | 164,122 (0%) | 0% | 0 | Common Stock | |
| James Hinrichs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 4,588 | 50,514 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 10,485 | 10,485 | - | - | Performance Share Units | |
| Michael E. Paolucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 4,588 | 19,779 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | Chief Legal & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 11,534 | 11,534 | - | - | Performance Share Units | |
| John Sicard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 4,588 | 10,919 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 12,058 | 12,058 | - | - | Performance Share Units | |
| Lilly Marks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 4,588 | 25,794 (0%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2020 | 45,872 | 45,872 | - | - | Performance Share Units | |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.78 per share. | 05 Jun 2020 | 8,750 | 56,683 (0%) | 0% | 21.8 | 190,575 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2020 | 8,750 | 0 | - | - | Stock Option (Right to Buy) | |
| Michael M. Finegan | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 37.41 per share. | 05 Jun 2020 | 8,750 | 47,933 (0%) | 0% | 37.4 | 327,323 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.66 per share. | 01 Apr 2020 | 319 | 47,933 (0%) | 0% | 26.7 | 8,505 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.09 per share. | 01 Apr 2020 | 365 | 48,252 (0%) | 0% | 26.1 | 9,523 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 7,666 | 17,675 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 24,542 | 24,542 | - | - | Stock Option (right to buy) | |
| Kimberley A. Elting | Chief Legal & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 26,996 | 26,996 | - | - | Stock Option (right to buy) | |
| Kimberley A. Elting | Chief Legal & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 8,432 | 36,344 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | Chief Legal & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.09 per share. | 01 Apr 2020 | 350 | 27,912 (0%) | 0% | 26.1 | 9,132 | Common Stock |
| Kimberley A. Elting | Chief Legal & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.66 per share. | 01 Apr 2020 | 335 | 36,009 (0%) | 0% | 26.7 | 8,931 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.66 per share. | 01 Apr 2020 | 363 | 55,636 (0%) | 0% | 26.7 | 9,678 | Common Stock |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 8,816 | 55,999 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.09 per share. | 01 Apr 2020 | 381 | 47,183 (0%) | 0% | 26.1 | 9,940 | Common Stock |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 28,223 | 28,223 | - | - | Stock Option (right to buy) | |
| Jon Carl Serbousek | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 33,538 | 75,266 (0%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 107,372 | 107,372 | - | - | Stock Option (right to buy) | |
| Ronald A. Matricaria | Director | Purchase of securities on an exchange or from another person at price $ 24.25 per share. | 16 Mar 2020 | 20,000 | 154,939 (0%) | 0% | 24.3 | 485,000 | Common Stock |
| James Hinrichs | Director | Purchase of securities on an exchange or from another person at price $ 26.85 per share. | 12 Mar 2020 | 10,000 | 45,574 (0%) | 0% | 26.8 | 268,469 | Common Stock |
| Jon Carl Serbousek | Director, CEO | Purchase of securities on an exchange or from another person at price $ 35.48 per share. | 27 Feb 2020 | 2,900 | 41,728 (0%) | 0% | 35.5 | 102,895 | Common Stock |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2019 | 33,395 | 33,395 | - | - | Stock Option (right to buy) | |
| Kevin J. Kenny | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2019 | 10,009 | 10,009 (0%) | 0% | 0 | Common Stock | |
| Jon Carl Serbousek | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2019 | 81,449 | 81,449 | - | - | Stock Option (right to buy) | |
| Jon Carl Serbousek | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2019 | 24,085 | 38,828 (0%) | 0% | 0 | Common Stock | |
| Bradley R. Mason | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.03 per share. | 31 Oct 2019 | 5,142 | 159,899 (0%) | 0% | 42.0 | 216,118 | Common Stock |
| Ronald A. Matricaria | None | Purchase of securities on an exchange or from another person at price $ 42.28 per share. | 31 Oct 2019 | 200 | 134,000 (0%) | 0% | 42.3 | 8,455 | Common Stock |
| Ronald A. Matricaria | None | Purchase of securities on an exchange or from another person at price $ 42.30 per share. | 31 Oct 2019 | 100 | 134,100 (0%) | 0% | 42.3 | 4,230 | Common Stock |
| Ronald A. Matricaria | None | Purchase of securities on an exchange or from another person at price $ 42.27 per share. | 31 Oct 2019 | 19,700 | 133,800 (0%) | 0% | 42.3 | 832,621 | Common Stock |
| Kimberley A. Elting | Chief Legal & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 54.26 per share. | 26 Sep 2019 | 550 | 26,499 (0%) | 0% | 54.3 | 29,843 | Common stock |
| James Hinrichs | None | Gift of securities by or to the insider at price $ 51.99 per share. | 12 Sep 2019 | 1,975 | 35,023 (0%) | 0% | 52.0 | 102,680 | Common Stock |
| Kimberley A. Elting | Chief Legal & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.61 per share. | 05 Sep 2019 | 365 | 27,049 (0%) | 0% | 50.6 | 18,473 | Common stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 50.97 per share. | 28 Aug 2019 | 5,805 | 165,041 (0%) | 0% | 51.0 | 295,874 | Common Stock |
| Jon Carl Serbousek | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2019 | 50,711 | 50,711 | - | - | Stock Option (right to boy) | |
| Jon Carl Serbousek | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2019 | 14,743 | 14,743 (0%) | 0% | 0 | Common Stock | |
| Bradley R. Mason | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.84 per share. | 11 Jul 2019 | 1,493 | 170,846 (0%) | 0% | 51.8 | 77,397 | Common Stock |
| Bradley R. Mason | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.27 per share. | 11 Jul 2019 | 1,741 | 172,339 (0%) | 0% | 52.3 | 91,002 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.84 per share. | 11 Jul 2019 | 363 | 48,617 (0%) | 0% | 51.8 | 18,818 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.27 per share. | 11 Jul 2019 | 395 | 48,980 (0%) | 0% | 52.3 | 20,647 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.88 per share. | 11 Jul 2019 | 452 | 49,375 (0%) | 0% | 52.9 | 23,902 | Common Stock |
| Brad Niemann | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.27 per share. | 11 Jul 2019 | 319 | 39,557 (0%) | 0% | 52.3 | 16,674 | Common Stock |
| Brad Niemann | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.84 per share. | 11 Jul 2019 | 293 | 38,970 (0%) | 0% | 51.8 | 15,189 | Common Stock |
| Brad Niemann | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.21 per share. | 11 Jul 2019 | 294 | 39,263 (0%) | 0% | 52.2 | 15,350 | Common Stock |
| Brad Niemann | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.88 per share. | 11 Jul 2019 | 363 | 39,876 (0%) | 0% | 52.9 | 19,195 | Common Stock |
| Kimberley A. Elting | Chief Legal & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.84 per share. | 11 Jul 2019 | 346 | 27,414 (0%) | 0% | 51.8 | 17,937 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.88 per share. | 11 Jul 2019 | 435 | 44,919 (0%) | 0% | 52.9 | 23,003 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.84 per share. | 11 Jul 2019 | 373 | 44,169 (0%) | 0% | 51.8 | 19,336 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.27 per share. | 11 Jul 2019 | 377 | 44,542 (0%) | 0% | 52.3 | 19,706 | Common Stock |
| Bradley R. Mason | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2019 | 18,150 | 0 | - | - | Performance Share Units | |
| Bradley R. Mason | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2019 | 18,150 | 174,080 (0%) | 0% | 0 | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2019 | 3,625 | 49,827 (0%) | 0% | 0 | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2019 | 3,625 | 0 | - | - | Performance Share Units | |
| Brad Niemann | President of Global Spine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2019 | 3,330 | 0 | - | - | Performance Share Units | |
| Brad Niemann | President of Global Spine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2019 | 3,330 | 40,239 (0%) | 0% | 0 | Common Stock | |
| Davide Bianchi | President, Global Extremities | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2019 | 3,330 | 0 | - | - | Performance Share Units | |
| Davide Bianchi | President, Global Extremities | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2019 | 3,330 | 38,526 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2019 | 3,937 | 45,354 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2019 | 3,937 | 0 | - | - | Performance Share Units | |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 51.44 per share. | 13 Jun 2019 | 3,123 | 155,930 (0%) | 0% | 51.4 | 160,638 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 50.93 per share. | 13 Jun 2019 | 5,767 | 159,053 (0%) | 0% | 50.9 | 293,689 | Common Stock |
| Alexis V. Lukianov | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 3,431 | 10,733 (0%) | 0% | 0 | Common Stock | |
| Maria Sainz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 3,431 | 35,833 (0%) | 0% | 0 | Common Stock | |
| Ronald A. Matricaria | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 6,373 | 114,100 (0%) | 0% | 0 | Common Stock | |
| James Hinrichs | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 3,431 | 36,998 (0%) | 0% | 0 | Common Stock | |
| Michael E. Paolucci | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 3,431 | 14,860 (0%) | 0% | 0 | Common Stock | |
| John Sicard | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 3,431 | 6,331 (0%) | 0% | 0 | Common Stock | |
| Lilly Marks | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 3,431 | 20,696 (0%) | 0% | 0 | Common Stock | |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 54.41 per share. | 14 May 2019 | 300 | 164,820 (0%) | 0% | 54.4 | 16,324 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 53.69 per share. | 14 May 2019 | 10,368 | 165,120 (0%) | 0% | 53.7 | 556,638 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 24 Apr 2019 | 958 | 41,417 (0%) | 0% | 0 | Common Stock | |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 52.52 per share. | 17 Apr 2019 | 3,749 | 175,488 (0%) | 0% | 52.5 | 196,897 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 52.07 per share. | 17 Apr 2019 | 2,200 | 179,237 (0%) | 0% | 52.1 | 114,547 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 09 Apr 2019 | 319 | 46,202 (0%) | 0% | 0 | Common Stock | |
| Brad Niemann | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 09 Apr 2019 | 248 | 36,909 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | Chief Legal & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 09 Apr 2019 | 335 | 27,760 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 09 Apr 2019 | 363 | 42,375 (0%) | 0% | 0 | Common Stock | |
| Bradley R. Mason | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 35,587 | 181,437 (0%) | 0% | 0 | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 7,549 | 46,521 (0%) | 0% | 0 | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 6,673 | 6,673 | - | - | Performance Share Units | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 11,055 | 11,055 | - | - | Stock Option (right to buy) | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 3,336 | 38,972 (0%) | 0% | 0 | Common Stock | |
| Brad Niemann | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 7,206 | 7,206 | - | - | Performance Share Units | |
| Brad Niemann | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 11,939 | 11,939 | - | - | Stock Option (right to buy) | |
| Brad Niemann | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 7,402 | 37,157 (0%) | 0% | 0 | Common Stock | |
| Brad Niemann | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 3,603 | 29,755 (0%) | 0% | 0 | Common Stock | |
| Davide Bianchi | President, Global Extremities | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 6,228 | 6,228 | - | - | Performance Share Units | |
| Davide Bianchi | President, Global Extremities | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 10,318 | 10,318 | - | - | Stock Option (right to buy) | |
| Davide Bianchi | President, Global Extremities | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 7,366 | 35,196 (0%) | 0% | 0 | Common Stock | |
| Davide Bianchi | President, Global Extremities | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 3,114 | 27,830 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | Chief Legal & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 3,603 | 20,508 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | Chief Legal & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 7,206 | 7,206 | - | - | Performance Share Units | |
| Kimberley A. Elting | Chief Legal & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 11,939 | 11,939 | - | - | Stock Option (right to buy) | |
| Kimberley A. Elting | Chief Legal & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 7,587 | 28,095 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 3,915 | 35,040 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 7,829 | 7,829 | - | - | Performance Share Units | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 12,971 | 12,971 | - | - | Stock Option (right to buy) | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 7,698 | 42,738 (0%) | 0% | 0 | Common Stock | |
| Bradley R. Mason | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.06 per share. | 11 Mar 2019 | 13,141 | 145,850 (0%) | 0% | 57.1 | 749,825 | Common Stock |
| Bradley R. Mason | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2019 | 16,700 | 158,991 (0%) | 0% | 0 | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.06 per share. | 11 Mar 2019 | 3,620 | 35,636 (0%) | 0% | 57.1 | 206,557 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2019 | 4,050 | 39,256 (0%) | 0% | 0 | Common Stock | |
| Brad Niemann | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2019 | 3,700 | 29,061 (0%) | 0% | 0 | Common Stock | |
| Brad Niemann | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.06 per share. | 11 Mar 2019 | 2,909 | 26,152 (0%) | 0% | 57.1 | 165,988 | Common Stock |
| Davide Bianchi | President, Global Extremities | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2019 | 4,050 | 24,716 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2019 | 4,425 | 34,606 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.06 per share. | 11 Mar 2019 | 3,481 | 31,125 (0%) | 0% | 57.1 | 198,626 | Common Stock |
| Davide Bianchi | President, Global Extremities | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 15 Feb 2019 | 24,199 | 20,666 (0%) | 0% | 65 | 1,572,935 | Common Stock |
| Davide Bianchi | President, Global Extremities | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 15 Feb 2019 | 201 | 44,865 (0%) | 0% | 65 | 13,065 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 14 Jan 2019 | 3,200 | 133,401 (0%) | 0% | 50 | 160,000 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 50.37 per share. | 14 Jan 2019 | 1,800 | 136,601 (0%) | 0% | 50.4 | 90,665 | Common Stock |
| Bradley R. Mason | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.52 per share. | 26 Dec 2018 | 9,440 | 138,401 (0%) | 0% | 51.5 | 486,349 | Common Stock |
| Brad Niemann | President of Global Spine | Sale of securities on an exchange or to another person at price $ 61.63 per share. | 04 Nov 2018 | 387 | 25,361 (0%) | 0% | 61.6 | 23,851 | Common Stock |
| Brad Niemann | President of Global Spine | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.46 per share. | 04 Nov 2018 | 966 | 25,748 (0%) | 0% | 61.5 | 59,370 | Common Stock |
| Luke T. Faulstick | None | Sale of securities on an exchange or to another person at price $ 60.92 per share. | 02 Nov 2018 | 3,600 | 7,179 (0%) | 0% | 60.9 | 219,330 | Common Stock |
| Luke T. Faulstick | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.13 per share. | 02 Nov 2018 | 4,300 | 10,779 (0%) | 0% | 32.1 | 138,159 | Common Stock |
| Luke T. Faulstick | None | Sale of securities on an exchange or to another person at price $ 60.93 per share. | 02 Nov 2018 | 3,500 | 7,129 (0%) | 0% | 60.9 | 213,245 | Common Stock |
| Luke T. Faulstick | None | Sale of securities on an exchange or to another person at price $ 61.72 per share. | 02 Nov 2018 | 650 | 6,479 (0%) | 0% | 61.7 | 40,121 | Common Stock |
| Luke T. Faulstick | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2018 | 4,300 | 25,700 | - | - | Stock Option (right to buy) | |
| Luke T. Faulstick | None | Sale of securities on an exchange or to another person at price $ 61.74 per share. | 02 Nov 2018 | 700 | 6,479 (0%) | 0% | 61.7 | 43,215 | Common Stock |
| Kimberley A. Elting | Chief Legal & Admin Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.89 per share. | 02 Nov 2018 | 7,000 | 22,740 (0%) | 0% | 42.9 | 300,230 | Common Stock |
| Kimberley A. Elting | Chief Legal & Admin Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2018 | 7,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Kimberley A. Elting | Chief Legal & Admin Officer | Sale of securities on an exchange or to another person at price $ 61.05 per share. | 02 Nov 2018 | 7,000 | 15,740 (0%) | 0% | 61.0 | 427,337 | Common Stock |
| Douglas C. Rice | CFO | Sale of securities on an exchange or to another person at price $ 61.84 per share. | 02 Nov 2018 | 200 | 26,311 (0%) | 0% | 61.8 | 12,368 | Common Stock |
| Douglas C. Rice | CFO | Sale of securities on an exchange or to another person at price $ 61.23 per share. | 02 Nov 2018 | 5,857 | 26,511 (0%) | 0% | 61.2 | 358,636 | Common Stock |
| Douglas C. Rice | CFO | Sale of securities on an exchange or to another person at price $ 55.65 per share. | 11 Oct 2018 | 3,949 | 32,368 (0%) | 0% | 55.6 | 219,754 | Common Stock |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.29 per share. | 03 Oct 2018 | 590 | 36,317 (0%) | 0% | 56.3 | 33,211 | Common Stock |
| Kimberley A. Elting | Chief Legal & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.79 per share. | 26 Sep 2018 | 550 | 15,740 (0%) | 0% | 56.8 | 31,235 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 53.02 per share. | 05 Sep 2018 | 2,500 | 147,841 (0%) | 0% | 53.0 | 132,555 | Common Stock |
| Kimberley A. Elting | Chief Legal & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2018 | 3,714 | 16,290 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.35 per share. | 04 Sep 2018 | 245 | 36,907 (0%) | 0% | 53.4 | 13,071 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 53.95 per share. | 07 Aug 2018 | 500 | 150,641 (0%) | 0% | 54.0 | 26,977 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 53.02 per share. | 07 Aug 2018 | 1,400 | 151,141 (0%) | 0% | 53.0 | 74,225 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 55.14 per share. | 07 Aug 2018 | 300 | 150,341 (0%) | 0% | 55.1 | 16,543 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 51.41 per share. | 07 Aug 2018 | 300 | 152,541 (0%) | 0% | 51.4 | 15,423 | Common Stock |
| Alexis V. Lukianov | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 2,900 | 6,966 (0%) | 0% | 0 | Common Stock | |
| Maria Sainz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 2,900 | 32,167 (0%) | 0% | 0 | Common Stock | |
| Luke T. Faulstick | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 2,900 | 10,629 (0%) | 0% | 0 | Common Stock | |
| Ronald A. Matricaria | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 5,274 | 106,887 (0%) | 0% | 0 | Common Stock | |
| James Hinrichs | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 2,900 | 29,197 (0%) | 0% | 0 | Common Stock | |
| Michael E. Paolucci | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 2,900 | 11,429 (0%) | 0% | 0 | Common Stock | |
| John Sicard | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 2,900 | 2,900 (0%) | 0% | 0 | Common Stock | |
| Lilly Marks | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2018 | 2,900 | 16,929 (0%) | 0% | 0 | Common Stock | |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 58.62 per share. | 10 Jul 2018 | 2,500 | 134,290 (0%) | 0% | 58.6 | 146,554 | Common Stock |
| Brad Niemann | President of Global Spine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.78 per share. | 02 Jul 2018 | 6,250 | 38,242 (0%) | 0% | 21.8 | 136,125 | Common Stock |
| Brad Niemann | President of Global Spine | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2018 | 2,989 | 26,992 (0%) | 0% | 0 | Common Stock | |
| Brad Niemann | President of Global Spine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2018 | 5,000 | 0 | - | - | Stock Option (right to buy) | |
| Brad Niemann | President of Global Spine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2018 | 6,250 | 0 | - | - | Stock Option (right to buy) | |
| Brad Niemann | President of Global Spine | Sale of securities on an exchange or to another person at price $ 57.35 per share. | 02 Jul 2018 | 2,150 | 26,992 (0%) | 0% | 57.4 | 123,309 | Common Stock |
| Brad Niemann | President of Global Spine | Sale of securities on an exchange or to another person at price $ 56.94 per share. | 02 Jul 2018 | 9,100 | 29,142 (0%) | 0% | 56.9 | 518,126 | Common Stock |
| Brad Niemann | President of Global Spine | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.37 per share. | 02 Jul 2018 | 5,000 | 31,992 (0%) | 0% | 27.4 | 136,850 | Common Stock |
| Raymond Fujikawa | President Spine Fixation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2018 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Raymond Fujikawa | President Spine Fixation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2018 | 8,750 | 0 | - | - | Stock Option (right to buy) | |
| Raymond Fujikawa | President Spine Fixation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.75 per share. | 20 Jun 2018 | 10,000 | 36,352 (0%) | 0% | 22.8 | 227,500 | Common Stock |
| Raymond Fujikawa | President Spine Fixation | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.78 per share. | 20 Jun 2018 | 8,750 | 45,102 (0%) | 0% | 21.8 | 190,575 | Common Stock |
| Raymond Fujikawa | President Spine Fixation | Sale of securities on an exchange or to another person at price $ 60.16 per share. | 20 Jun 2018 | 28,047 | 17,055 (0%) | 0% | 60.2 | 1,687,369 | Common Stock |
| Raymond Fujikawa | President Spine Fixation | Sale of securities on an exchange or to another person at price $ 60.49 per share. | 20 Jun 2018 | 4,196 | 12,859 (0%) | 0% | 60.5 | 253,833 | Common Stock |
| Davide Bianchi | President Extremity Fixation | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 19 Jun 2018 | 14,762 | 41,260 (0%) | 0% | 60 | 885,720 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2018 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Michael M. Finegan | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 58.63 per share. | 18 Jun 2018 | 19,275 | 47,569 (0%) | 0% | 58.6 | 1,130,172 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 25.01 per share. | 18 Jun 2018 | 20,000 | 66,844 (0%) | 0% | 25.0 | 500,200 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2018 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.95 per share. | 18 Jun 2018 | 10,000 | 46,844 (0%) | 0% | 29.0 | 289,500 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 59.13 per share. | 18 Jun 2018 | 10,725 | 36,844 (0%) | 0% | 59.1 | 634,128 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 57.95 per share. | 14 Jun 2018 | 2,500 | 143,221 (0%) | 0% | 57.9 | 144,864 | Common Stock |
| Ronald A. Matricaria | None | Purchase of securities on an exchange or from another person at price $ 51.97 per share. | 03 May 2018 | 10,000 | 101,613 (0%) | 0% | 52.0 | 519,724 | Common Stock |
| Bradley R. Mason | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 37,102 | 37,102 | - | - | Performance Share Units | |
| Bradley R. Mason | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 18,551 | 147,572 (0%) | 0% | 0 | Common Stock | |
| Bradley R. Mason | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 65,857 | 65,857 | - | - | Stock Option (right to buy) | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 2,857 | 32,794 (0%) | 0% | 0 | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 10,144 | 10,144 | - | - | Stock Option (right to buy) | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 5,715 | 5,715 | - | - | Performance Share Units | |
| Brad Niemann | President Biostim | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 2,528 | 21,296 (0%) | 0% | 0 | Common Stock | |
| Brad Niemann | President Biostim | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 5,055 | 5,055 | - | - | Performance Share Units | |
| Brad Niemann | President Biostim | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 8,973 | 8,973 | - | - | Stock Option (right to buy) | |
| Davide Bianchi | President Extremity Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 5,055 | 5,055 | - | - | Performance Share Units | |
| Davide Bianchi | President Extremity Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 2,528 | 51,972 (0%) | 0% | 0 | Common Stock | |
| Davide Bianchi | President Extremity Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 8,973 | 8,973 | - | - | Stock Option (right to buy) | |
| Kimberley A. Elting | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 6,814 | 6,814 | - | - | Performance Share Units | |
| Kimberley A. Elting | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 12,095 | 12,095 | - | - | Stock Option (right to buy) | |
| Kimberley A. Elting | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 3,407 | 12,790 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 13,109 | 13,109 | - | - | Stock Option (right to buy) | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 3,693 | 34,870 (0%) | 0% | 0 | Common Stock | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 7,385 | 7,385 | - | - | Performance Share Units | |
| Raymond Fujikawa | President Spine Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 8,193 | 8,193 | - | - | Stock Option (right to buy) | |
| Raymond Fujikawa | President Spine Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 4,616 | 4,616 | - | - | Performance Share Units | |
| Raymond Fujikawa | President Spine Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 2,308 | 26,352 (0%) | 0% | 0 | Common Stock | |
| Robert A. Goodwin | President Biologics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 2,198 | 22,257 (0%) | 0% | 0 | Common Stock | |
| Robert A. Goodwin | President Biologics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 4,396 | 4,396 | - | - | Performance Share Units | |
| Robert A. Goodwin | President Biologics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2018 | 7,803 | 7,803 | - | - | Stock Option (right to buy) | |
| John Sicard | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2018 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Brad Niemann | President Biostim | Sale of securities on an exchange or to another person at price $ 52.08 per share. | 11 Dec 2017 | 5,547 | 34,631 (0%) | 0% | 52.1 | 288,861 | Common Stock |
| Bradley R. Mason | Director, CEO | Sale of securities on an exchange or to another person at price $ 53.48 per share. | 28 Nov 2017 | 5,000 | 183,053 (1%) | 0% | 53.5 | 267,400 | Common Stock |
| Luke T. Faulstick | None | Sale of securities on an exchange or to another person at price $ 51.22 per share. | 06 Nov 2017 | 4,800 | 7,729 (0%) | 0% | 51.2 | 245,846 | Common Stock |
| Davide Bianchi | President Extremity Fixation | Sale or transfer of securities back to the company at price $ 49.72 per share. | 12 Sep 2017 | 500 | 59,103 (0%) | 0% | 49.7 | 24,859 | Common Stock |
| Brad Niemann | President Biostim | Sale of securities on an exchange or to another person at price $ 49.44 per share. | 11 Sep 2017 | 6,956 | 40,178 (0%) | 0% | 49.4 | 343,926 | Common stock |
| Douglas C. Rice | CFO | Sale of securities on an exchange or to another person at price $ 49.46 per share. | 11 Sep 2017 | 7,353 | 44,743 (0%) | 0% | 49.5 | 363,689 | Common stock |
| Robert A. Goodwin | President Biologics | Sale or transfer of securities back to the company at price $ 48.29 per share. | 24 Aug 2017 | 6,205 | 31,127 (0%) | 0% | 48.3 | 299,655 | Common stock |
| Bradley R. Mason | CEO | Sale of securities on an exchange or to another person at price $ 48.10 per share. | 21 Aug 2017 | 2,733 | 188,053 (1%) | 0% | 48.1 | 131,457 | Common Stock |
| Raymond Fujikawa | President Spine Fixation | Sale of securities on an exchange or to another person at price $ 47.06 per share. | 10 Aug 2017 | 6,364 | 31,084 (0%) | 0% | 47.1 | 299,502 | Common Stock |
| Alexis V. Lukianov | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 3,579 | 3,579 (0%) | 0% | 0 | Common Stock | |
| Bradley R. Mason | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 30,369 | 30,369 | - | - | Performance Share Units | |
| Bradley R. Mason | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 15,184 | 190,786 (1%) | 0% | 0 | Common Stock | |
| Bradley R. Mason | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 52,990 | 52,990 | - | - | Stock Option (right to buy) | |
| Maria Sainz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 3,579 | 28,812 (0%) | 0% | 0 | Common Stock | |
| Luke T. Faulstick | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 3,579 | 12,529 (0%) | 0% | 0 | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 6,508 | 6,508 | - | - | Performance Share Units | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 3,254 | 47,522 (0%) | 0% | 0 | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 11,355 | 11,355 | - | - | Stock Option (right to buy) | |
| Ronald A. Matricaria | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 6,508 | 90,394 (0%) | 0% | 0 | Common Stock | |
| James Hinrichs | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 3,579 | 29,638 (0%) | 0% | 0 | Common Stock | |
| Brad Niemann | President Biostim | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 2,983 | 47,134 (0%) | 0% | 0 | Common Stock | |
| Brad Niemann | President Biostim | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 5,965 | 5,965 | - | - | Performance Share Units | |
| Brad Niemann | President Biostim | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 10,409 | 10,409 | - | - | Stock Option (right to buy) | |
| Davide Bianchi | President Extremity Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 5,965 | 5,965 | - | - | Performance Share Units | |
| Davide Bianchi | President Extremity Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 10,409 | 10,409 | - | - | Stock Option (right to buy) | |
| Davide Bianchi | President Extremity Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 2,983 | 59,603 (0%) | 0% | 0 | Common Stock | |
| Michael E. Paolucci | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 3,579 | 7,529 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 3,525 | 9,125 (0%) | 0% | 0 | Common Stock | |
| Kimberley A. Elting | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 12,301 | 12,301 | - | - | Stock Option (right to buy) | |
| Kimberley A. Elting | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 7,050 | 7,050 | - | - | Performance Share Units | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 13,248 | 13,248 | - | - | Stock Option (right to buy) | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 7,592 | 7,592 | - | - | Performance Share Units | |
| Douglas C. Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 3,796 | 52,096 (0%) | 0% | 0 | Common Stock | |
| Lilly Marks | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 3,579 | 14,029 (0%) | 0% | 0 | Common Stock | |
| Raymond Fujikawa | President Spine Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 2,440 | 37,448 (0%) | 0% | 0 | Common Stock | |
| Raymond Fujikawa | President Spine Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 8,516 | 8,516 | - | - | Stock Option (right to buy) | |
| Raymond Fujikawa | President Spine Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 4,881 | 4,881 | - | - | Performance Share Units | |
| Robert A. Goodwin | President Biologics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 4,881 | 4,881 | - | - | Performance Share Units | |
| Robert A. Goodwin | President Biologics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 8,516 | 8,516 | - | - | Stock Option (right to buy) | |
| Robert A. Goodwin | President Biologics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2017 | 2,440 | 37,332 (0%) | 0% | 0 | Common Stock | |
| Bradley R. Mason | CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2017 | 6,667 | 0 | - | - | Stock Option (right to buy) | |
| Bradley R. Mason | CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.97 per share. | 26 Jun 2017 | 6,667 | 187,422 (1%) | 0% | 45.0 | 299,815 | Common Stock |
| Bradley R. Mason | CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.32 per share. | 26 Jun 2017 | 6,555 | 180,867 (1%) | 0% | 46.3 | 303,628 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.32 per share. | 26 Jun 2017 | 21,961 | 45,614 (0%) | 0% | 46.3 | 1,017,234 | Common Stock |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2017 | 22,300 | 0 | - | - | Stock Option (right to buy) | |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.97 per share. | 26 Jun 2017 | 22,300 | 67,575 (0%) | 0% | 45.0 | 1,002,831 | Common Stock |
| Alexis V. Lukianov | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2016 | 30,000 | 30,000 | - | - | Stock Option | |
| Bradley R. Mason | CEO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 08 Nov 2016 | 4,538 | 146,681 | - | - | Common Stock | |
| Bradley R. Mason | CEO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 08 Nov 2016 | 5,000 | 151,219 | - | - | Common Stock | |
| Brad Niemann | President Biostim | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2016 | 9,820 | 39,534 | - | - | Common Stock | |
| Kimberley A. Elting | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2016 | 22,000 | 22,000 | - | - | Stock Option (right to buy) | |
| Kimberley A. Elting | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2016 | 5,600 | 5,600 | - | - | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2016 | 10,000 | 51,670 | - | - | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2016 | 10,000 | 10,000 | - | - | Stock Option | |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2016 | 10,000 | 61,670 | - | - | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2016 | 5,000 | 0 | - | - | Stock Option | |
| Michael M. Finegan | Chief Strategy Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 01 Sep 2016 | 25,000 | 41,670 | - | - | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2016 | 10,000 | 0 | - | - | Stock Option | |
| Michael M. Finegan | Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2016 | 5,000 | 66,670 | - | - | Common Stock | |
| Guy J. Jordan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 3,950 | 19,720 | - | - | Common Stock | |
| Ronald A. Matricaria | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 7,200 | 82,667 | - | - | Common Stock | |
| Luke T. Faulstick | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 3,950 | 8,950 | - | - | Common Stock | |
| Anthony F. Martin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 3,950 | 15,450 | - | - | Common Stock | |
| Bradley R. Mason | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 17,707 | 156,219 | - | - | Common Stock | |
| Bradley R. Mason | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 36,300 | 36,300 | - | - | Performance Share Units | |
| Bradley R. Mason | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 63,525 | 63,525 | - | - | Stock Option (right to buy) | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 7,250 | 7,250 | - | - | Performance Share Units | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 3,537 | 41,670 | - | - | Common Stock | |
| Michael M. Finegan | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 12,688 | 12,688 | - | - | Stock Option (right to buy) | |
| Maria Sainz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 3,950 | 24,778 | - | - | Common Stock | |
| James Hinrichs | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 3,950 | 25,450 | - | - | Common Stock | |
| Brad Niemann | President Biostim | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 3,249 | 30,601 | - | - | Common Stock | |
| Brad Niemann | President Biostim | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 6,660 | 6,660 | - | - | Performance Share Units | |
| Brad Niemann | President Biostim | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 11,655 | 11,655 | - | - | Stock Option (right to buy) | |
| Davide Bianchi | Pres, Extremity Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 6,660 | 6,660 | - | - | Performance Share Units | |
| Davide Bianchi | Pres, Extremity Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 3,249 | 41,936 | - | - | Common Stock | |
| Davide Bianchi | Pres, Extremity Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 11,655 | 11,655 | - | - | Stock Option (right to buy) | |
| Michael E. Paolucci | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 3,950 | 4,950 | - | - | Common Stock | |
| Doug Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 13,781 | 13,781 | - | - | Stock Option (right to buy) | |
| Doug Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 3,841 | 36,686 | - | - | Common Stock | |
| Doug Rice | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 7,875 | 7,875 | - | - | Performance Share Units | |
| Lilly Marks | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 3,950 | 10,450 | - | - | Common Stock | |
| Raymond Fujikawa | President Spine Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 9,538 | 9,538 | - | - | Stock Option (right to buy) | |
| Raymond Fujikawa | President Spine Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 5,450 | 5,450 | - | - | Performance Share Units | |
| Raymond Fujikawa | President Spine Fixation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 2,659 | 27,826 | - | - | Common Stock | |
| Robert A. Goodwin | President Biologics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 2,659 | 30,128 | - | - | Common Stock | |
| Robert A. Goodwin | President Biologics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 5,450 | 5,450 | - | - | Performance Share Units | |
| Robert A. Goodwin | President Biologics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2016 | 9,538 | 9,538 | - | - | Stock Option (right to buy) | |
| Maria Sainz | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 10 Jun 2016 | 4,157 | 20,828 | - | - | Common Stock | |
| Bradley R. Mason | CEO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 09 Jun 2016 | 18,336 | 141,920 | - | - | Common Stock | |
| Bradley R. Mason | CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2016 | 20,000 | 0 | - | - | Stock Option | |
| Bradley R. Mason | CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2016 | 20,000 | 160,256 | - | - | Common Stock | |
| Brad Niemann | President Biostim | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 08 Jun 2016 | 3,402 | 28,275 | - | - | Common Stock | |
| Brad Niemann | President Biostim | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2016 | 2,775 | 31,677 | - | - | Common Stock | |
| Brad Niemann | President Biostim | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2016 | 2,775 | 8,325 | - | - | Stock Option |